Note: It’s important to read the entire article. It states that alcohol use and smoking can contribute to Parkinson’s disease. Studies have found that people with hepatitis C (as a group) are more likely to drink more alcohol and smoke cigarettes. Furthermore, prior studies have not found a link between hepatitis B and Parkinson’s disease. I think this study is interesting but we need larger more definitive research. Alan
MINNEAPOLIS – The viruses hepatitis B and C may both be associated with an increased risk of Parkinson’s disease, according to a study published in the March 29, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology. The hepatitis virus affects the liver.
According to the Centers for Disease Control and Prevention (CDC), it is estimated that anywhere from 850,000 to 2.2 million people in the United States have chronic hepatitis B virus infection and anywhere from 2.7 to 3.9 million people have chronic hepatitis C. While both can lead to serious illness, many people have few symptoms and do not realize they have the virus, especially at first.
Hepatitis B is spread through contact with blood and body fluids of an infected person, such as unprotected sex, sharing needles, getting a tattoo or piercing with unsterilized tools or sharing razors or toothbrushes with an infected person.
A GROUP of charities, led by Médecins Sans Frontières, is fighting to have a drug’s patent revoked by the European Patent Office. Sofosbuvir can cure hepatitis C in just three months, but costs up to €55,000 for a course of treatment.
“There are 80 million people in the world with hepatitis C, but only 5.4 million have access to the drug”
The drug’s patent is held by pharmaceuticals firm Gilead of Foster City, California, giving the company a monopoly over the drug in Europe.
(CHRISTIANSBURG, Va.) – The New River Valley has elevated rates of acute hepatitis C, and numbers are increasing every year.
Antonio Brown Jr., a public health associate from the Centers for Disease Control and Prevention (CDC), works to prevent hepatitis C transmission in the New River Valley. During his two-year fellowship with the New River Health District Academic Health Department and Virginia Tech he will develop a comprehensive hepatitis C prevention plan. His work includes conducting interviews, identifying and investigating new cases and providing prevention education.
“Since 2012, more than 1,000 cases of hepatitis C have been reported in the New River Health District,” said District Health Director Noelle Bissell, M.D. “We have seen significant numbers of cases of acute hepatitis C infection linked to tattoo parlors, the use of homemade tattoo guns at parties and in people who report more than 10 sex partners. We’re also noticing a trend in cases associated with intravenous drug abuse, particularly methamphetamine, and in pregnant women and women of childbearing age.”
Health experts have devised an aggressive plan to stamp out a viral disease that is fueling a sharp rise in liver cancer in the United States and killing 20,000 Americans per year.
Their national strategy for eliminating two types of hepatitis by 2030 hinges on persuading the federal government to purchase the rights to one or more of the costly new medications that can essentially cure hepatitis C.
That unprecedented step is one of a raft of recommendations issued Tuesday by the National Academies of Sciences, Engineering, and Medicine. The academies’ expert panel also recommended a campaign to vaccinate all adults against hepatitis B, expanding needle exchanges for intravenous drug users and a nationwide effort to identify and treat the legions of Americans who are unknowingly infected with either strain of the virus.
Each year, hepatitis B virus and hepatitis C virus cause nearly 1.5 million deaths worldwide—more than HIV, tuberculosis, and malaria. Such loss of life comes at a cost to society through the direct expense of treatment as well as through the loss of adults in their prime. In an effort to describe a strategy for eliminating viral hepatitis as a U.S. public health problem by 2030, the National Academies, with support from the Centers for Disease Control and Prevention and the U.S. Department of Health and Human Services, the American Association for the Study of Liver Diseases, the Infectious Diseases Society of America, and the National Viral Hepatitis Roundtable, convened an expert committee to outline a national strategy. The committee produced two reports. The first report, Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report, concluded that both hepatitis B and C could be eliminated as a public health problem in the United States, but that there are substantial obstacles to meeting this goal. This second report, A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report, recommends specific actions to hasten the end of these diseases and lays out five areas—information, interventions, service delivery, financing, and research—to consider in the national plan.